Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q53835547)
Watch
English
The place of PD-1 inhibitors in melanoma management.
scientific article
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
title
The place of PD-1 inhibitors in melanoma management.
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
author
Paul Lorigan
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
author name string
Samantha Bowyer
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
publication date
23 June 2015
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
published in
Lancet Oncology Commission
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
volume
16
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
issue
8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
page(s)
873-874
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
cites work
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Expanded access programmes: patient interests versus clinical trial integrity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pembrolizumab versus Ipilimumab in Advanced Melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nivolumab in previously untreated melanoma without BRAF mutation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
PD-1 blockade induces responses by inhibiting adaptive immune resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900094-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(15)00094-7
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
PubMed publication ID
26115798
1 reference
stated in
Europe PubMed Central
PubMed publication ID
26115798
retrieved
20 May 2018
reference URL
http://europepmc.org/abstract/MED/26115798
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
